Presented by: University of Kentucky Department of Pathology

“Diagnostic Integration in Primary Liver Tumors: Bridging Morphology, Immunophenotype, and Molecular Insight”

Mohamed Hussein, MD

Faculty Candidate

Thursday, November 13, 2025

12:00 – 1:00pm

In-Person MS 147 or Zoom: http://us06web.zoom.us/j/89110280273? pwd=ybybn06jFDKtJzTCALTtz15lG8vhKV.1We

PASSCODE: 281106

 Use the QR code to register for this Grand Rounds if you have not already registered.

At the completion of this lecture attendees should be able to:

• • Recognize key morphologic patterns that distinguish major categories of primary liver tumors, including hepatocellular, cholangiocytic, and mixed-lineage neoplasms.
  • Apply an evidence-based immunohistochemical approach to resolve common diagnostic dilemmas in liver tumor pathology.
  • Correlate morphologic and immunophenotypic findings with molecular alterations relevant to classification, prognosis, and targeted therapy.
  • Navigate diagnostic “gray zones” through integrative interpretation rather than reliance on single modalities.
  • Understand the clinical and therapeutic implications of accurate subclassification and integrated reporting of primary liver tumors.

Disclosure of Financial Interest Summary to Learners
All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.
None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.
The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.
Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation